By Marie Rosenthal
The FDA approved brexanolone (Zulresso, Sage Therapeutics) injection, the first medication to receive approval specifically for postpartum depression (PPD).
PPD is a major depressive episode that occurs following childbirth, although symptoms can start during pregnancy. As with other forms of depression, it is characterized by sadness and/or loss of interest in activities that one used to enjoy and anhedonia, and may present with symptoms such as cognitive impairment, feelings